Drug Trial News

RSS

2-in-1 budesonide-formoterol inhaler reduces children's asthma attacks by 45%

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated.

29 Sep 2025

Clinical trial disproves claims that antioxidant supplement boosts male fertility

A large Dutch randomized clinical trial (SUMMER) found that a widely marketed antioxidant supplement (Impryl) did not improve ongoing pregnancy rates in men seeking fertility care. Instead, pregnancy success was significantly lower in the critical 4–6 month treatment window, raising safety concerns.

28 Sep 2025

Ocrelizumab provides superior control of multiple sclerosis relapses compared to other therapies

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.

23 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

New dialysis filter shows promise for improving survival and health in kidney failure patients

Researchers at London Health Sciences Centre Research Institute (LHSCRI) and Western University's Schulich School of Medicine & Dentistry have launched a clinical trial that is evaluating a new type of dialysis filter called Elisio HX that may significantly improve outcomes for people living with kidney failure across Canada.

22 Sep 2025

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the body's own insulin production and slow the progression of type 1 diabetes (T1D) in people recently diagnosed with the condition.

19 Sep 2025

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Clinical trial reveals encouraging results for apitegromab in spinal muscular atrophy

A new clinical trial has revealed encouraging results for a muscle-targeting therapy aimed at improving motor function in children and adolescents with spinal muscular atrophy, according to a study published in The Lancet Neurology.

18 Sep 2025

Investigational drug reduces hot flashes and night sweats for post-menopausal women

The investigational drug elinzanetant significantly reduces hot flashes and night sweats for post-menopausal women, a large, international clinical trial has found.

18 Sep 2025

University of Houston co-leads national study on atropine eyedrops for nearsightedness prevention

The University of Houston is co-leading a national study, the first of its kind in the United States, exploring whether atropine eyedrops can delay the onset of nearsightedness in young children and lessen its progression over a lifetime, a project with potential to shape future standards in vision care.

18 Sep 2025

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.

17 Sep 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal today [Monday, 8th September 2025] show that patients with mesothelioma - a rare cancer of the lining of the lung that may be caused by exposure to asbestos - who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.

9 Sep 2025

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S., launched an innovative national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

9 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Aspirin therapy does not help people suffering from chronic rhinosinusitis with nasal polyps

A randomized placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive to non-steroidal anti-inflammatory drugs (NSAIDs).

8 Sep 2025

Previous
1
...
3
4
5
6
7
8
9
...
1161
Next

Drug Trial News

2-in-1 budesonide-formoterol inhaler reduces children's asthma attacks by 45%

Clinical trial disproves claims that antioxidant supplement boosts male fertility

Ocrelizumab provides superior control of multiple sclerosis relapses compared to other therapies

Orforglipron pill improves heart and metabolic risk factors in trial

New dialysis filter shows promise for improving survival and health in kidney failure patients

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Clinical trial reveals encouraging results for apitegromab in spinal muscular atrophy

Investigational drug reduces hot flashes and night sweats for post-menopausal women

University of Houston co-leads national study on atropine eyedrops for nearsightedness prevention

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Aspirin therapy does not help people suffering from chronic rhinosinusitis with nasal polyps

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News